{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:47:29Z","timestamp":1793159249052,"version":"4.5.0"},"reference-count":80,"publisher":"Georg Thieme Verlag KG","issue":"04","funder":[{"name":"Basic Science Research Program","award":["NRF-2015R1A5A2008833"],"award-info":[{"award-number":["NRF-2015R1A5A2008833"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during antithrombotic therapies compared with Caucasian patients. As potent P2Y12 receptor inhibitors (e.g., ticagrelor and prasugrel) and direct oral anticoagulants are commonly used in current daily practice, the unique risk\u2013benefit trade-off in East Asians has been a topic of emerging interest. In this article, we propose updated evidence and future directions of antithrombotic treatment in East Asian patients.<\/jats:p>","DOI":"10.1055\/s-0040-1718729","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T18:40:15Z","timestamp":1605033615000},"page":"422-432","source":"Crossref","is-referenced-by-count":328,"title":["The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease"],"prefix":"10.1055","volume":"121","author":[{"given":"Hyun Kuk","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Chosun University Hospital, Gwangju, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udaya S.","family":"Tantry","sequence":"additional","affiliation":[{"name":"Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, Maryland, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Sidney C.","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of North Carolina, Chapel Hill, North Carolina, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung Ho","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Chonnam National University Hospital, Gwangju, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Jung","family":"Park","sequence":"additional","affiliation":[{"name":"The Heart Institute, Asan Medical Center, University of Ulsan, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3468-6453","authenticated-orcid":false,"given":"Moo Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dong-A University Hospital, Busan, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Sun","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cardiovascular Center, Korea University Anam Hospital, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Seok","family":"Shin","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Ulsan Hospital, Ulsan, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duk-Woo","family":"Park","sequence":"additional","affiliation":[{"name":"The Heart Institute, Asan Medical Center, University of Ulsan, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Huo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Peking University First Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Liang","family":"Chen","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Nanjing First Hospital, Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Bo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Peking University First Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6821-1504","authenticated-orcid":false,"given":"Shinya","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Medicine (Cardiology), Tokai University School of Medicine, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[{"name":"National Cerebral and Cardiovascular Center, Suita, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jone","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cardiology Division, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National University Heart Centre Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aradi","sequence":"additional","affiliation":[{"name":"Heart Centre Balatonf\u00fcred and Heart and Vascular Centre, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Geisler","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Cardiovascular Medicine, University Hospital of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana A.","family":"Gorog","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College, London, United Kingdom"},{"name":"Postgraduate Medical School, University of Hertfordshire, Hertfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Sibbing","sequence":"additional","affiliation":[{"name":"Department of Cardiology, LMU M\u00fcnchen, Munich, Germany"},{"name":"DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Gurbel","sequence":"additional","affiliation":[{"name":"Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, Maryland, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Hoon","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital, Changwon, South Korea"},{"name":"Institute of the Health Sciences, Gyeongsang National University, Jinju, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,11,10]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11886-014-0485-4","article-title":"\u201cEast asian paradox\u201d: challenge for the current antiplatelet strategy of \u201cone-guideline-fits-all races\u201d in acute coronary syndrome","volume":"16","author":"Y H Jeong","year":"2014","journal-title":"Curr Cardiol Rep"},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","article-title":"Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI","volume":"11","author":"G N Levine","year":"2014","journal-title":"Nat Rev Cardiol"},{"issue":"05","key":"ref3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2174\/1570161116666180117103238","article-title":"Should antithrombotic treatment strategies in east asians differ from Caucasians?","volume":"16","author":"J S Bae","year":"2018","journal-title":"Curr Vasc Pharmacol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.scib.2018.12.020","article-title":"2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI","volume":"64","author":"Y Huo","year":"2019","journal-title":"Sci Bull (Beijing)"},{"key":"ref5","first-page":"38","article-title":"What is the \u201cEast Asian Paradox\u201d?","volume":"1","author":"Y H Jeong","year":"2012","journal-title":"Cardiosource Interventional News"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update","volume":"94","author":"S A Scott","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"05","key":"ref7","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jcin.2008.06.011","article-title":"Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents","volume":"1","author":"D W Park","year":"2008","journal-title":"JACC Cardiovasc Interv"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(07)60314-6","article-title":"Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study","volume":"369","author":"J Daemen","year":"2007","journal-title":"Lancet"},{"issue":"16","key":"ref9","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"D Sibbing","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"issue":"09","key":"ref10","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1161\/CIRCRESAHA.115.307016","article-title":"Platelet-mediated thrombosis: from bench to bedside","volume":"118","author":"P A Gurbel","year":"2016","journal-title":"Circ Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijcard.2015.04.180","article-title":"Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: the ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation, Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study","volume":"190","author":"K Lee","year":"2015","journal-title":"Int J Cardiol"},{"issue":"04","key":"ref12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3109\/09537104.2013.815341","article-title":"Predictive values of post-clopidogrel platelet reactivity assessed by different platelet function tests on ischemic events in East Asian patients treated with PCI","volume":"25","author":"H Z Zhang","year":"2014","journal-title":"Platelets"},{"issue":"02","key":"ref13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ahj.2010.10.036","article-title":"Comparison of 2 point-of-care platelet function tests, VerifyNow assay and multiple electrode platelet aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention","volume":"161","author":"Y G Ko","year":"2011","journal-title":"Am Heart J"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ijcard.2015.01.026","article-title":"Optimal cutoff value of P2Y12 reaction units to prevent major adverse cardiovascular events in the acute periprocedural period: post-hoc analysis of the randomized PRASFIT-ACS study","volume":"182","author":"M Nakamura","year":"2015","journal-title":"Int J Cardiol"},{"issue":"03","key":"ref15","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jacc.2010.08.631","article-title":"Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial","volume":"57","author":"J W Suh","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jcin.2011.12.009","article-title":"Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction","volume":"5","author":"S G Ahn","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.amjcard.2011.07.012","article-title":"Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study)","volume":"108","author":"K W Park","year":"2011","journal-title":"Am J Cardiol"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.ijcard.2012.04.154","article-title":"High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting","volume":"167","author":"H Y Jin","year":"2013","journal-title":"Int J Cardiol"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41598-017-18134-y","article-title":"Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: a prospective multicentre registry study","volume":"8","author":"H J Joo","year":"2018","journal-title":"Sci Rep"},{"issue":"01","key":"ref20","first-page":"34.e1","article-title":"Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention","volume":"165","author":"D W Park","year":"2013","journal-title":"Am Heart J"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijcard.2016.01.102","article-title":"The challenge for predicting bleeding events by assessing platelet reactivity following coronary stenting","volume":"207","author":"S Y Choi","year":"2016","journal-title":"Int J Cardiol"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1055\/s-0038-1676545","article-title":"Racial differences in ischaemia\/bleeding risk trade-off during anti-platelet therapy: individual patient level landmark meta-analysis from seven RCTs","volume":"119","author":"J Kang","year":"2019","journal-title":"Thromb Haemost"},{"issue":"09","key":"ref24","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics-2020 update: a report from the American Heart Association","volume":"141","author":"S S Virani","year":"2020","journal-title":"Circulation"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"301.e11","DOI":"10.1016\/j.gheart.2014.11.004","article-title":"Biomarkers of coronary artery disease differ between asians and caucasians in the general population","volume":"10","author":"C M Gijsberts","year":"2015","journal-title":"Glob Heart"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(06)68263-9","article-title":"Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls","volume":"367","author":"Z Ye","year":"2006","journal-title":"Lancet"},{"issue":"06","key":"ref27","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1160\/TH11-04-0214","article-title":"Current antithrombotic treatment in East Asia: some perspectives on anticoagulation and antiplatelet therapy","volume":"107","author":"C Ma","year":"2012","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref28","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","article-title":"Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis","volume":"153","author":"J KY Hooi","year":"2017","journal-title":"Gastroenterology"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/1747493016647736","article-title":"Location of cerebral atherosclerosis: Why is there a difference between East and West?","volume":"13","author":"J S Kim","year":"2018","journal-title":"Int J Stroke"},{"issue":"19","key":"ref30","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/eurheartj\/ehy807","article-title":"Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial","volume":"40","author":"T F Chao","year":"2019","journal-title":"Eur Heart J"},{"issue":"03","key":"ref31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1055\/s-0038-1626697","article-title":"Third-generation P2Y12 inhibitors in East Asian acute myocardial infarction patients: a nationwide prospective multicentre study","volume":"118","author":"J Kang","year":"2018","journal-title":"Thromb Haemost"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2019.09.011","article-title":"Clinical outcomes after ticagrelor and clopidogrel in Chinese post-stented patients","volume":"290","author":"Y Sun","year":"2019","journal-title":"Atherosclerosis"},{"issue":"23","key":"ref33","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1161\/CIRCULATIONAHA.119.041766","article-title":"Clinically significant bleeding with ticagrelor versus clopidogrel in korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial","volume":"140","author":"D W Park","year":"2019","journal-title":"Circulation"},{"issue":"03","key":"ref34","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3390\/jcm9030652","article-title":"Efficacy and safety of long-term and short-term dual antiplatelet therapy: a meta-analysis of comparison between Asians and non-Asians","volume":"9","author":"Y J Ki","year":"2020","journal-title":"J Clin Med"},{"issue":"03","key":"ref35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention","volume":"140","author":"P Urban","year":"2019","journal-title":"Circulation"},{"issue":"24","key":"ref36","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"H Watanabe","year":"2019","journal-title":"JAMA"},{"issue":"24","key":"ref37","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"J Y Hahn","year":"2019","journal-title":"JAMA"},{"issue":"23","key":"ref38","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"B K Kim","year":"2020","journal-title":"JAMA"},{"issue":"07","key":"ref39","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1253\/circj.CJ-13-1482","article-title":"Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study","volume":"78","author":"S Saito","year":"2014","journal-title":"Circ J"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(20)31791-8","article-title":"Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial","volume":"10257","author":"H S Kim","year":"2020","journal-title":"Lancet"},{"issue":"08","key":"ref41","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: The TAILOR-PCI randomized clinical trial","volume":"324","author":"N L Pereira","year":"2020","journal-title":"JAMA"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvaa005","article-title":"Practical guidance for P2Y12 inhibitors in acute myocardial infarction undergoing percutaneous coronary intervention","author":"S H Lee","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"04","key":"ref43","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41569-019-0314-y","article-title":"Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease","volume":"17","author":"D Capodanno","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"18","key":"ref44","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1161\/CIRCULATIONAHA.118.033580","article-title":"Combination antiplatelet and oral anticoagulant therapy in patients with coronary and peripheral artery disease","volume":"139","author":"P A Gurbel","year":"2019","journal-title":"Circulation"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02103-w","article-title":"The Impact of platelet-fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease","author":"J S Bae","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"14","key":"ref46","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"J W Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"S S Anand","year":"2018","journal-title":"Lancet"},{"issue":"04","key":"ref48","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1055\/s-0039-1678527","article-title":"Management of patients with asymptomatic and symptomatic carotid artery disease: update on anti-thrombotic therapy","volume":"119","author":"D Pastori","year":"2019","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref49","first-page":"396","article-title":"Rivaroxaban in stable cardiovascular disease","volume":"378","author":"Y H Jeong","year":"2018","journal-title":"N Engl J Med"},{"issue":"04","key":"ref50","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jacc.2007.01.098","article-title":"Racial\/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation","volume":"50","author":"A Y Shen","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"02","key":"ref51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4070\/kcj.2019.0099","article-title":"Impact of anticoagulation intensity in Korean patients with atrial fibrillation: is it different from western population?","volume":"50","author":"K H Lee","year":"2020","journal-title":"Korean Circ J"},{"issue":"03","key":"ref52","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1055\/s-0039-3401823","article-title":"Lower versus standard INR targets in atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials","volume":"120","author":"A K Pandey","year":"2020","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref53","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1055\/s-0040-1702230","article-title":"Should we adopt a standard international normalized ratio range of 2.0 to 3.0 for Asian patients with atrial fibrillation? An appeal for evidence-based management, not eminence-based recommendations","volume":"120","author":"T F Chao","year":"2020","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref54","doi-asserted-by":"crossref","first-page":"169","DOI":"10.5853\/jos.2016.00052","article-title":"Asian patients with stroke plus atrial fibrillation and the dose of non-vitamin k oral anticoagulants","volume":"18","author":"O Y Bang","year":"2016","journal-title":"J Stroke"},{"issue":"02","key":"ref55","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1160\/TH11-08-0551","article-title":"Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate","volume":"107","author":"S H\u00e4rtter","year":"2012","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref56","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2133\/dmpk.DMPK-12-RG-109","article-title":"Confirmation of model-based dose selection for a Japanese phase III study of rivaroxaban in non-valvular atrial fibrillation patients","volume":"28","author":"M Kaneko","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref57","first-page":"153","article-title":"Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects","volume":"10","author":"C Frost","year":"2018","journal-title":"Clin Pharmacol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.118.023093","article-title":"Outcomes after use of standard- and low-dose non-vitamin k oral anticoagulants in asian patients with atrial fibrillation","author":"M S Cho","year":"2018","journal-title":"Stroke"},{"issue":"03","key":"ref59","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.chest.2019.04.108","article-title":"Effectiveness and safety of four direct oral anticoagulants in asian patients with nonvalvular atrial fibrillation","volume":"156","author":"Y H Chan","year":"2019","journal-title":"Chest"},{"issue":"12","key":"ref60","doi-asserted-by":"crossref","first-page":"e014177","DOI":"10.1161\/JAHA.119.014177","article-title":"Label adherence of direct oral anticoagulants dosing and clinical outcomes in patients with atrial fibrillation","volume":"9","author":"H T Yu","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"03","key":"ref61","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"J Knuuti","year":"2020","journal-title":"Eur Heart J"},{"issue":"12","key":"ref62","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"S Yasuda","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"ref63","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1111\/j.1538-7836.2011.04443.x","article-title":"Racial differences in venous thromboembolism","volume":"9","author":"N A Zakai","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref64","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/jth.12464","article-title":"Incidence of venous thromboembolism in different ethnic groups: a regional direct comparison study","volume":"12","author":"S Liao","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref65","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.atherosclerosis.2009.04.020","article-title":"C-reactive protein levels and risk of mortality from cardiovascular disease in Japanese: the JACC Study","volume":"207","author":"H Iso","year":"2009","journal-title":"Atherosclerosis"},{"issue":"06","key":"ref66","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1373\/clinchem.2007.098996","article-title":"Ethnic differences in C-reactive protein concentrations","volume":"54","author":"A Kelley-Hedgepeth","year":"2008","journal-title":"Clin Chem"},{"issue":"10","key":"ref67","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.amjcard.2004.01.067","article-title":"C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study)","volume":"93","author":"M A Albert","year":"2004","journal-title":"Am J Cardiol"},{"issue":"12","key":"ref68","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1111\/j.1538-7836.2006.02237.x","article-title":"Plasma hemostatic factors and endothelial markers in four racial\/ethnic groups: the MESA study","volume":"4","author":"P L Lutsey","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref69","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/CIRCULATIONAHA.109.907998","article-title":"Does black ethnicity influence the development of stent thrombosis in the drug-eluting stent era?","volume":"122","author":"S D Collins","year":"2010","journal-title":"Circulation"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"1076029620943671","DOI":"10.1177\/1076029620943671","article-title":"Coagulation status and venous thromboembolism risk in African Americans: a potential risk factor in COVID-19","volume":"26","author":"G H Frydman","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"issue":"12","key":"ref71","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/nm.3385","article-title":"Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c","volume":"19","author":"L C Edelstein","year":"2013","journal-title":"Nat Med"},{"issue":"23","key":"ref72","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1182\/blood-2014-04-572479","article-title":"Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race","volume":"124","author":"L C Edelstein","year":"2014","journal-title":"Blood"},{"issue":"13","key":"ref73","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.jcin.2020.04.020","article-title":"Prognostic impact of race in patients undergoing PCI: analysis from 10 randomized coronary stent trials","volume":"13","author":"M Golomb","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"issue":"04","key":"ref74","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1160\/TH13-08-0643","article-title":"Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes","volume":"111","author":"Y H Jeong","year":"2014","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref75","doi-asserted-by":"crossref","first-page":"e001167","DOI":"10.1161\/JAHA.114.001167","article-title":"Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients","volume":"3","author":"E I Lev","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02240-2","article-title":"Viscoelastic properties of clot formation and their clinical impact in East Asian versus Caucasian patients with stable coronary artery disease: a COMPARE-RACE analysis","author":"Y H Jeong","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"06","key":"ref77","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1055\/s-0040-1710317","article-title":"Hypercoagulation and antithrombotic treatment in coronavirus 2019: a new challenge","volume":"120","author":"F Violi","year":"2020","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref78","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1055\/s-0040-1710019","article-title":"Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines","volume":"120","author":"Z Zhai","year":"2020","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref79","doi-asserted-by":"crossref","first-page":"e19934","DOI":"10.2196\/19934","article-title":"Why African Americans are a potential target for COVID-19 infection in the United States","volume":"22","author":"A Hamidian Jahromi","year":"2020","journal-title":"J Med Internet Res"},{"issue":"23","key":"ref80","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1016\/j.jacc.2020.04.031","article-title":"COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review","volume":"75","author":"B Bikdeli","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"06","key":"ref81","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/bjh.16749","article-title":"COVID19 coagulopathy in Caucasian patients","volume":"189","author":"H Fogarty","year":"2020","journal-title":"Br J Haematol"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1718729.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T11:11:55Z","timestamp":1669547515000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1718729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":80,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2021,3,21]]},"published-print":{"date-parts":[[2021,4]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1718729","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,10]]}}}